Mitragynin (Swedish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mitragynin" in Swedish language version.

refsWebsite

Global rank Swedish rank

12nih.gov

4^th place

17^th place

11doi.org

2^nd place

14^th place

3europa.eu

68^th place

52^nd place

2lakemedelsverket.se

low place

155^th place

2fda.gov

447^th place

1,667^th place

1scientificamerican.com

896^th place

839^th place

1worktribe.com

low place

doi.org (Global: 2^nd place; Swedish: 14^th place)

dx.doi.org

”From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction”. Neuroscience and Biobehavioral Reviews 37 (2): sid. 138–151. February 2013. doi:10.1016/j.neubiorev.2012.11.012. PMID 23206666.
”The pharmacology and toxicology of kratom: from traditional herb to drug of abuse”. International Journal of Legal Medicine 130 (1): sid. 127–138. January 2016. doi:10.1007/s00414-015-1279-y. PMID 26511390.
”Current perspectives on the impact of Kratom use”. Substance Abuse and Rehabilitation 10: sid. 23–31. 2019. doi:10.2147/SAR.S164261. PMID 31308789.
”Kratom use and mental health: A systematic review”. Drug and Alcohol Dependence 183: sid. 134–140. February 2018. doi:10.1016/j.drugalcdep.2017.10.012. PMID 29248691.
”Neurobiology of Kratom and its main alkaloid mitragynine”. Brain Research Bulletin 126 (Pt 1): sid. 29–40. September 2016. doi:10.1016/j.brainresbull.2016.03.015. PMID 27018165.
”Update on the Pharmacology and Legal Status of Kratom”. The Journal of the American Osteopathic Association 116 (12): sid. 802–809. December 2016. doi:10.7556/jaoa.2016.156. PMID 27893147.
”Kratom and Future Treatment for the Opioid Addiction and Chronic Pain: Periculo Beneficium?”. Current Drug Targets 20 (2): sid. 166–172. 2018-12-19. doi:10.2174/1389450118666170425154120. PMID 28443503.
”Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review”. Asian Journal of Psychiatry 43: sid. 73–82. June 2019. doi:10.1016/j.ajp.2019.05.016. PMID 31100603.
”Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists”. Science Signaling 13 (625). March 2020. doi:10.1126/scisignal.aaz3140. PMID 32234959. https://nottingham-repository.worktribe.com/output/4193457.
”Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands”. Journal of Medicinal Chemistry 45 (9): sid. 1949–1956. April 2002. doi:10.1021/jm010576e. PMID 11960505.
”An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration”. Journal of Dietary Supplements 10 (2): sid. 152–170. June 2013. doi:10.3109/19390211.2013.793541. PMID 23725528.

europa.eu (Global: 68^th place; Swedish: 52^nd place)

emcdda.europa.eu

”Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status)”. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). http://www.emcdda.europa.eu/publications/drug-profiles/kratom.
”Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status)”. Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status). European Monitoring Centre for Drugs and Drug Addiction. 8 January 2015. http://www.emcdda.europa.eu/publications/drug-profiles/kratom#control.
”EMCDDA | Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status)” (på engelska). www.emcdda.europa.eu. http://www.emcdda.europa.eu/publications/drug-profiles/kratom.

fda.gov (Global: 447^th place; Swedish: 1,667^th place)

”FDA and kratom”. FDA and kratom. US Food and Drug Administration. 3 April 2019. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom.
”Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse”. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. US Food and Drug Administration. 6 February 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm595622.htm.

lakemedelsverket.se (Global: low place; Swedish: 155^th place)

Åtta nya ämnen narkotikaklassade, pressmeddelande från Läkemedelsverket 2011-09-01
Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika

nih.gov (Global: 4^th place; Swedish: 17^th place)

ncbi.nlm.nih.gov

”From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction”. Neuroscience and Biobehavioral Reviews 37 (2): sid. 138–151. February 2013. doi:10.1016/j.neubiorev.2012.11.012. PMID 23206666.
”The pharmacology and toxicology of kratom: from traditional herb to drug of abuse”. International Journal of Legal Medicine 130 (1): sid. 127–138. January 2016. doi:10.1007/s00414-015-1279-y. PMID 26511390.
”Current perspectives on the impact of Kratom use”. Substance Abuse and Rehabilitation 10: sid. 23–31. 2019. doi:10.2147/SAR.S164261. PMID 31308789.
”Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects”. The Journal of the American Osteopathic Association 112 (12): sid. 792–799. December 2012. PMID 23212430.
”Kratom use and mental health: A systematic review”. Drug and Alcohol Dependence 183: sid. 134–140. February 2018. doi:10.1016/j.drugalcdep.2017.10.012. PMID 29248691.
”Neurobiology of Kratom and its main alkaloid mitragynine”. Brain Research Bulletin 126 (Pt 1): sid. 29–40. September 2016. doi:10.1016/j.brainresbull.2016.03.015. PMID 27018165.
”Update on the Pharmacology and Legal Status of Kratom”. The Journal of the American Osteopathic Association 116 (12): sid. 802–809. December 2016. doi:10.7556/jaoa.2016.156. PMID 27893147.
”Kratom and Future Treatment for the Opioid Addiction and Chronic Pain: Periculo Beneficium?”. Current Drug Targets 20 (2): sid. 166–172. 2018-12-19. doi:10.2174/1389450118666170425154120. PMID 28443503.
”Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review”. Asian Journal of Psychiatry 43: sid. 73–82. June 2019. doi:10.1016/j.ajp.2019.05.016. PMID 31100603.
”Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists”. Science Signaling 13 (625). March 2020. doi:10.1126/scisignal.aaz3140. PMID 32234959. https://nottingham-repository.worktribe.com/output/4193457.
”Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands”. Journal of Medicinal Chemistry 45 (9): sid. 1949–1956. April 2002. doi:10.1021/jm010576e. PMID 11960505.
”An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration”. Journal of Dietary Supplements 10 (2): sid. 152–170. June 2013. doi:10.3109/19390211.2013.793541. PMID 23725528.

scientificamerican.com (Global: 896^th place; Swedish: 839^th place)

”Recreational Drug Kratom Hits the Same Brain Receptors as Strong Opioids” (på engelska). Chemical & Engineerin News. https://www.scientificamerican.com/article/recreational-drug-kratom-hits-the-same-brain-receptors-as-strong-opioids/.

worktribe.com (Global: low place; Swedish: low place)

nottingham-repository.worktribe.com

”Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists”. Science Signaling 13 (625). March 2020. doi:10.1126/scisignal.aaz3140. PMID 32234959. https://nottingham-repository.worktribe.com/output/4193457.

Mitragynin (Swedish Wikipedia)

doi.org (Global: 2nd place; Swedish: 14th place)

dx.doi.org

europa.eu (Global: 68th place; Swedish: 52nd place)